Iclepertin for schizophrenia

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 4 registered trials.

Why this status

  1. 15 Apr 2021: Trial registered, NCT04846868
  2. 15 Apr 2021: Trial registered, NCT04846881
  3. 27 Apr 2021: Trial registered, NCT04860830
  4. 9 Aug 2021: Trial started, NCT04860830
  5. 24 Aug 2021: Trial started, NCT04846881
  6. 8 Sep 2021: Trial started, NCT04846868

The trials

NCT04846868: Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-1)

State
Completed
Phase
Phase 3
People
620 taking part
Started
8 Sep 2021
Primary completion
17 Sep 2024
Arms
Iclepertin 10 mg
Results
Posted on the registry
  1. 15 Apr 2021: Trial registered
  2. 8 Sep 2021: Trial started
  3. 1 Oct 2024: Trial completed
  4. 5 Nov 2025: Trial results posted

NCT04846881: Clinical Trial of Iclepertin Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)

State
Completed
Phase
Phase 3
People
611 taking part
Started
24 Aug 2021
Primary completion
18 Oct 2024
Arms
Iclepertin 10 mg
Results
Posted on the registry
  1. 15 Apr 2021: Trial registered
  2. 24 Aug 2021: Trial started
  3. 17 Nov 2024: Trial completed
  4. 12 Dec 2025: Trial results posted

NCT04860830: CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia

State
Completed
Phase
Phase 3
People
609 taking part
Started
9 Aug 2021
Primary completion
28 Oct 2024
Arms
Iclepertin 10 mg
Results
Posted on the registry
  1. 27 Apr 2021: Trial registered
  2. 9 Aug 2021: Trial started
  3. 20 Nov 2024: Trial completed
  4. 6 Feb 2026: Trial results posted

NCT05211947: A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study

State
Stopped early
Phase
Phase 3
People
1,356 taking part
Started
21 Mar 2022
Primary completion
26 Feb 2025
Arms
Iclepertin 10 mg
Results
Posted on the registry
  1. 27 Jan 2022: Trial registered
  2. 21 Mar 2022: Trial started
  3. 18 Mar 2025: Trial terminated
  4. 8 Apr 2026: Trial results posted

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.